The substance is identified as chlorzoxazone, with CAS Registry Number 95-25-0, molecular formula C₇H₄ClNO₂, and relative molecular mass 169.57 g/mol. The designation “Chlorzoxazone USP (Export grade) Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” is a supply-chain classification rather than a separate pharmacopeial category. The material is released against the current United States Pharmacopeia Chlorzoxazone monograph and is manufactured under active pharmaceutical ingredient GMP aligned with ICH Q7. Chlorzoxazone is a centrally acting skeletal muscle relaxant intended primarily for solid oral dosage processing. Compendial and regulatory documentation for injectable use requires additional controls for bacterial endotoxin, sterility, particulate matter, and solubility because the API is practically insoluble in water. The material is a white or practically white crystalline powder; particle-size distribution and dissolution behavior are therefore central to formulation development. Export-grade release typically includes a certificate of analysis, GMP certificate, residual solvent statement, elemental impurity statement, nitrosamine risk evaluation, and a supply-chain audit trail for cross-border regulatory submission. The product differs from technical-grade chlorzoxazone principally in chromatographic purity, residual solvent control, elemental impurity control, and documented GMP status.

What Distinguishes Export-Grade Chlorzoxazone USP from Non-Compendial Technical Material?

Non-compendial chlorzoxazone is often supplied as an intermediate for organic synthesis or as a research chemical. Such material is not released under API GMP and may contain solvent residues above the limits assigned by ICH Q3C(R8) or elemental impurities above the permitted daily exposure limits of ICH Q3D. Export-grade chlorzoxazone USP is controlled for specified and unspecified impurities using the chromatographic procedure of the USP monograph. Each batch is assigned a retest date based on stability data generated under ICH Q1A(R2) conditions, and the manufacturer is required to maintain change-control records, deviation reports, and annual product quality reviews under ICH Q7 Section 12. The export-grade designation adds documentary continuity: shipping documentation must identify the API manufacturer, the site of release testing, and the regulatory status of the site. When the release testing site is different from the manufacturing site, the responsible qualified person must confirm that the testing site is identified in the marketing authorization dossier. Non-pharmaceutical material is not required to maintain these records.

For solid oral dosage manufacturing, the most consequential variable is not the nominal assay but the interaction between particle morphology and unit-operation selection. Chlorzoxazone crystals can exhibit platelet or acicular habits that reduce bulk density and increase the angle of repose; direct compression therefore becomes feeder-dependent and may require force-fed hoppers, vibrational densification, or dry granulation. Loss-in-weight gravimetric feeders fitted with agitation spokes are used when the as-received powder bridges in stainless-steel hoppers. Wet granulation in a high-shear vertical granulator followed by fluid-bed drying is a common processing route because the granulation step improves flow and content uniformity for low-dose tablet strengths. During high-shear granulation, impeller speed, chopper speed, and liquid binder addition rate must be linked to the material’s particle-size distribution measured by laser diffraction under USP <429>. A pre-blend with microcrystalline cellulose and croscarmellose sodium is typically used; the bulk powder is granulated with purified water or an aqueous binder solution, then dried to a loss-on-drying endpoint that meets the final tablet stability specification. In capsule filling, flowability at the dosing disk or tamping station requires periodic verification because batch-to-batch differences in particle aspect ratio can shift fill weight during prolonged production runs.

The practically insoluble nature of chlorzoxazone means that dissolution testing is a release criterion for finished tablets, not for the API alone. In formulation screening, dissolution media often include surfactants such as sodium lauryl sulfate; the concentration of surfactant must be linked to the USP <711> apparatus and to the acceptance criteria in the approved dosage form. Published data for this specific configuration is limited; therefore, formulation scientists select surfactant concentrations by screening bulk API across multiple particle-size values. Particle-size distributions are controlled by jet milling or pin milling, and the resulting surface area increase can shift dissolution rate disproportionately when the particle size is reduced below 10 µm because of aggregation and electrostatic charging. The same particle-size reduction, however, can reduce powder flow to an extent that direct compression is no longer viable. This processing conflict is the primary technical reason granulation routes dominate over direct compression for many chlorzoxazone tablet formulations.

When Injectable Dosage Feasibility Is Evaluated

Injectable use of chlorzoxazone is not a standard compendial presentation; published data for this specific configuration is limited. If the API is designated for oral and injectable processing, the manufacturer’s specification must be expanded beyond the oral solid dosage form. For injectable finished products, the excipient solution, the API particle burden, the bacterial endotoxin limit, and the route of administration determine the required controls. The bacterial endotoxin acceptance criterion is established under USP <85> and is expressed in endotoxin units per kilogram of body weight for the finished-product maximum dose; the API therefore requires a maximum endotoxin concentration consistent with those equations. For non-intrathecal parenteral routes, a common upper limit is 5 EU/kg/h; for intrathecal administration the limit is 0.2 EU/kg/h. Sterilization of the finished injection is governed by 21 CFR 211.113(b), but chlorzoxazone’s aqueous solubility limits the ability to formulate a simple aqueous solution. Co-solvent systems using propylene glycol, ethanol, or polyethylene glycol are possible only where the finished product remains physically stable after dilution and across the labeled pH range. Particulate matter in injectable products is controlled under USP <788>; API for injectable processing is therefore expected to be supplied with low subvisible particulate counts across the 10 µm and 25 µm channels, although no API-level monograph limit exists unless the supplier and the finished-product manufacturer agree to it in a quality agreement.

If a sterile aqueous solution is pursued, the calculated bacterial endotoxin limit for a non-intrathecal parenteral at a common 5 EU/kg/h threshold is divided by the maximum bolus dose in kilograms per hour; an API with a high unpurified endotoxin burden may fail this limit before formulation. The compendial monograph for chlorzoxazone does not automatically assign this calculation; therefore, the supplier’s bacterial endotoxin data must be reviewed against the intended maximum daily dose rather than a generic value.

The compendial assay window remains tight.

Quality release of chlorzoxazone USP is anchored to the current USP monograph and general chapters. The table below summarizes the release parameters that are typically fixed in export-grade specifications. Values are compendial defaults or standard pharmaceutical limits; the finished-product manufacturer must confirm each parameter against the current monograph because pharmacopeias are revised continuously.

Because pharmaceutical equivalence does not guarantee formulation equivalence, the API specification alone is insufficient to substitute one exporter’s chlorzoxazone with another without evaluating particle size, morphology, residual solvent profile, and D90-to-D10 width. On a manufacturing line, two batches with identical assay and impurity results can still differ in tablet press ejection force, friability, and content uniformity if the crystal habit differs. Export-grade suppliers therefore include a particle-size distribution report generated by laser diffraction using the same instrument and dispersion condition across batches. If the supplier changes the milling site, the finished-product manufacturer is required to evaluate the change under ICH Q7 Section 13 and regional post-approval change guidance. A pre-shipment sample with full CoA is standard for initial commercial batches; thereafter a reduced testing protocol may be adopted under a supplier-quality agreement. The material should be stored in tightly closed containers at controlled room temperature, protected from light. If the warehouse relative humidity exceeds 60% RH, the product should be reconditioned and re-tested only if the stability program supports such action.

The receiving site sampling plan for export-grade API containers is often based on the square root of the number of containers plus one for identity testing, with full testing performed on a representative composite sample. This approach is defined in the site quality agreement and is not a requirement of the USP monograph. For export shipments split across multiple lots, the supplier must maintain a lot genealogy that links each packed container to the original crystallizer batch. If a container is damaged in transit, the receiving site quarantines the material and evaluates it under a deviation record; re-release requires retesting at least for identity, assay, and water content.

Compared with other centrally acting skeletal muscle relaxants, chlorzoxazone is not a benzodiazepine and is not a direct neuromuscular blocker. Its reported mechanism differs from baclofen or tizanidine; the drug inhibits polysynaptic reflexes at spinal and supraspinal levels, although the exact mechanism is not fully characterized. For an API introduction, this distinction matters because the product is not interchangeable at the molecular level. If a purchaser is comparing chlorzoxazone USP with another API such as methocarbamol, the compendial identity tests, molecular formula, and pharmacologic classification must be considered independently of grade-level documentation. The export-grade designation applies only to chlorzoxazone; it does not imply equivalence to any other active ingredient.

Export Documentation and Audit-Trail Requirements

Export-grade chlorzoxazone requires a documentation package that aligns with the receiving market’s regulatory expectations. For shipments entering regulated pharmaceutical jurisdictions, the technical file includes the certificate of analysis linking the batch number to the purchase order; a certificate of GMP compliance issued by the competent authority in the exporting country; a statement of the manufacturing site’s regulatory establishment registration number; and a statement on residual solvents, elemental impurities, and nitrosamines. Nitrosamine risk assessment is prepared under current FDA and EMA frameworks, even though chlorzoxazone is not a secondary or tertiary amine; the assessment is retained as part of the quality system. The container closure system is specified by the supplier and is qualified under USP <660> for glass or USP <661.1> for plastic materials where applicable. The labeling must include the compendial name, grade, manufacturer, batch number, retest date, storage condition, and the phrase “For pharmaceutical use” where regional regulations require it. Each document is reviewed by a qualified person or authorized person before release in the receiving market.

A production-scale tableting process illustrates the control logic. A batch of export-grade chlorzoxazone with low bulk density may segregate less than a batch with high bulk density when transferred from an intermediate bulk container through a gravity-fed tablet press. However, bulk density is not a release criterion in the USP monograph; it is an additional agreed parameter. In dry granulation, the powder is compacted and milled, then the granules are measured for compressibility and compactibility using an instrumented tablet press during formulation development. If the ejection force rises above the limit defined by the lubricant system, the tablet may exhibit capping or lamination. In wet granulation, the endpoint is not defined solely by torque or power consumption; the granule moisture content after drying is controlled to a narrow loss-on-drying band and the particle size is confirmed by sieve analysis. These process checks are supported by USP <905> for content uniformity of the finished tablets and USP <1216> for tablet friability where applicable.